Presentation Feature of Lymphoma in the Kirkuk City
DOI:
https://doi.org/10.61841/dw5f8818Keywords:
Lymphoma, Hodgkin, Non Hodgkin, Chemotherapy, Ann Arbor staging systemAbstract
Lymphoma is one of the commonest cancer in the Iraq. While the incidence is only 3 % in the western world, in the middle ease almost 10 % of all cancer are lymphoid. Because of the advanced medicine in the developed world, most of the cases are diagnosed at early stages of the disease. In the underdeveloped and even developing world the situation seems to be different. The true object of this study was to screen our lymphoma patients at presentation to see the stage and pattern of their disease. This is simple descriptive study; performed from July 2018 to June 2019 that reviewed retrospectively in Kirkuk hematology oncology Cancer in Kirkuk city. The total number collected were 126 patients, the information were taken from records of the file system assigned for each patient in Kirkuk hematology oncology Cancer, Cases newly diagnosed with lymphoma, both sexes over ten years old were eligible to participate in this study. Stages of lymphoma are based on time of presentation and staged according to the Ann Arbor system, takes both types Hodgkin and Non Hodgkin Lymphoma with their subtypes and presence or absence of B symptoms. Lymphoma simply means cancer of lymph nodes and the lymphatic tissues in the body and most commonly occurring hematological malignancies which are comparable with other countries and consider as highly curable cancer in our patients. The frequency of Non Hodgkin lymphoma which is higher than Hodgkin lymphoma. Nodular sclerosis was the commonest histopathologicl subtypes in Hodgkin lymphoma, while in Non Hodgkin lymphoma diffuse large B cell was common. In Hodgkin lymphoma we found that peak age group of presentation was younger than Non Hodgkin lymphoma, male predominance in NHL & female predominance in HL and absence of B symptom are more common in our study.
Downloads
References
1. Hoff brand AV, Petti JE t. Essential hematology. 5t ed. Ital: Rotolito Lambarda SpA; 2016.
2. Stein H. Hodgkin lymphomas: Introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Pres;, 2011.
3. Thomas R.K, Re D, Wolf J, Diehl V. Part I. Hodgkin lymphoma: molecular biology of Hodgkin and Reed-Sterng cell. Lancet Oncol; 2014.
4. Jaffe ES, Harris NL, Stein H, et al, World Health Organization Classification of Tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissue. Lyon, France: IARC; 2011.
5. Govinde, Ramaswamy. The Washington Manual of Oncology. 2nded. USA: Lippincott Williams &Wilkins; 2018.
6. Stein H, Delsol G, Pileri S, et al. Classical Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2011.
7. Chiu BC, Wiesenberger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 2013; 4:161.
8. Montalban C, Garcia JF, Abraira V, Gonzalez-Camacho L, Morente MM, et al. Spanish Hodgkin's Lymphoma Study Group. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol; 2014.
9. Mauch PM , Armitage JO , Coiffier B , Dalla-Favera R , Harris n L. non Hodgkin lymphoma. Lippincott Williams & Wilkins, Philadelphi;.2014.
10. Abraham, James, Guiiey, Jame, Allegra, Carmen J. Bethesda Handbook of clinical oncology. 2nded. Lippincot Williams & Wilkin; 2015.
11. Casicato A, Denis, Associate editor Territo C. Mary .Manual of Clinical Oncology. 8hed. U.A: Lippincott Williams & Wilkins; 2019.
12. Fisher SG, Fisher RI. The epidemiology of non Hodgkin lymphoma. Oncogen; 2014.
13. Kantarjan M, HAGOP, WOLFF A, ROBERT. MD ANDERSON Manual of medical oncology.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
